• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

信使核糖核酸疫苗:控制传染病的新型武器。

mRNA vaccines: A novel weapon to control infectious diseases.

作者信息

Tian Yuying, Deng Zhuoya, Yang Penghui

机构信息

Faculty of Hepato-Pancreato-Biliary Surgery, Institute of Hepatobiliary Surgery, The First Medical Center, Chinese PLA General Hospital, Beijing, China.

Inner Mongolia Medical University, Hohhot, China.

出版信息

Front Microbiol. 2022 Oct 4;13:1008684. doi: 10.3389/fmicb.2022.1008684. eCollection 2022.

DOI:10.3389/fmicb.2022.1008684
PMID:36267192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9576954/
Abstract

Infectious diseases have always threatened human life, but with the development of vaccines, effective strategies for preventing and controlling these diseases have become available. The global outbreak of COVID-19 ushered in the advent of mRNA vaccine technologies, which quickly led to the introduction of mRNA vaccines effective against SARS-CoV-2. The success of this approach has stimulated research into the use of mRNA vaccines in the fight against other emerging as well as remerging infectious diseases. This review examines the constructive strategies and delivery systems used in mRNA vaccines and provides an overview of current clinical trials of those vaccines in the prevention of infectious diseases. The underlying mechanisms of mRNA vaccines are also discussed, including the double-edged sword of the innate immune response. Finally, the challenges but also the potential of mRNA vaccines are considered.

摘要

传染病一直威胁着人类生命,但随着疫苗的发展,预防和控制这些疾病的有效策略已经出现。新冠疫情的全球爆发迎来了mRNA疫苗技术的问世,这迅速催生了针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的有效mRNA疫苗。这种方法的成功激发了对mRNA疫苗用于对抗其他新出现和重新出现的传染病的研究。本综述探讨了mRNA疫苗中使用的构建策略和递送系统,并概述了这些疫苗目前在预防传染病方面的临床试验情况。还讨论了mRNA疫苗的潜在机制,包括先天免疫反应的双刃剑效应。最后,探讨了mRNA疫苗面临的挑战以及潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/0c620d87a581/fmicb-13-1008684-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/2e458d9d1900/fmicb-13-1008684-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/47390a397845/fmicb-13-1008684-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/89afdc51c4b7/fmicb-13-1008684-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/0c620d87a581/fmicb-13-1008684-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/2e458d9d1900/fmicb-13-1008684-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/47390a397845/fmicb-13-1008684-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/89afdc51c4b7/fmicb-13-1008684-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8fd/9576954/0c620d87a581/fmicb-13-1008684-g004.jpg

相似文献

1
mRNA vaccines: A novel weapon to control infectious diseases.信使核糖核酸疫苗:控制传染病的新型武器。
Front Microbiol. 2022 Oct 4;13:1008684. doi: 10.3389/fmicb.2022.1008684. eCollection 2022.
2
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
3
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic.mRNA 疫苗——克服 COVID-19 大流行的理想治疗策略。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2040330. doi: 10.1080/21645515.2022.2040330. Epub 2022 Mar 23.
4
The clinical progress and challenges of mRNA vaccines.信使核糖核酸疫苗的临床进展与挑战
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 Sep-Oct;15(5):e1894. doi: 10.1002/wnan.1894. Epub 2023 Apr 24.
5
The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview.基于RNA的疫苗在抗击新冠疫情中的重要性:概述
Vaccines (Basel). 2021 Nov 17;9(11):1345. doi: 10.3390/vaccines9111345.
6
Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants.针对新型冠状病毒及其新兴变种的先进疫苗设计策略
Bioengineering (Basel). 2023 Jan 22;10(2):148. doi: 10.3390/bioengineering10020148.
7
Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases.mRNA 疫苗分子设计与递送技术的最新进展:用于传染病防控
Front Immunol. 2022 Jul 15;13:896958. doi: 10.3389/fimmu.2022.896958. eCollection 2022.
8
Brief Insights into mRNA Vaccines: Their Successful Production and Nanoformulation for Effective Response against COVID-19 and Their Potential Success for Influenza A and B.mRNA疫苗简述:其成功生产及纳米制剂以有效应对新冠病毒,并探讨其对甲型和乙型流感的潜在成效
Pathogens. 2024 Jun 12;13(6):500. doi: 10.3390/pathogens13060500.
9
The Development of mRNA Vaccines for Infectious Diseases: Recent Updates.用于传染病的mRNA疫苗的发展:最新进展
Infect Drug Resist. 2021 Dec 9;14:5271-5285. doi: 10.2147/IDR.S341694. eCollection 2021.
10
COVID-19 mRNA vaccines: Platforms and current developments.COVID-19 mRNA 疫苗:平台和当前进展。
Mol Ther. 2022 May 4;30(5):1850-1868. doi: 10.1016/j.ymthe.2022.02.016. Epub 2022 Feb 19.

引用本文的文献

1
Alphaviral backbone of self-amplifying RNA enhances protein expression and immunogenicity against SARS-CoV-2 antigen.自我扩增RNA的甲病毒骨架增强了针对SARS-CoV-2抗原的蛋白质表达和免疫原性。
Mol Ther. 2025 Feb 5;33(2):514-528. doi: 10.1016/j.ymthe.2024.12.055. Epub 2024 Dec 30.
2
Influenza a Neuraminidase-Based Bivalent mRNA Vaccine Induces Th1-Type Immune Response and Provides Protective Effects in Mice.基于甲型流感病毒神经氨酸酶的二价mRNA疫苗在小鼠中诱导Th1型免疫反应并提供保护作用。
Vaccines (Basel). 2024 Mar 13;12(3):300. doi: 10.3390/vaccines12030300.
3
Delivery of nucleic acids using nanomaterials.

本文引用的文献

1
Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV conserved elements in macaques.在恒河猴中比较针对 HIV 保守元件的 mRNA/LNP 疫苗和 DNA 疫苗的免疫原性。
Front Immunol. 2022 Jul 22;13:945706. doi: 10.3389/fimmu.2022.945706. eCollection 2022.
2
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis.SARS-CoV-2 疫苗接种可引发以 CD8 T 细胞为主的肝炎。
J Hepatol. 2022 Sep;77(3):653-659. doi: 10.1016/j.jhep.2022.03.040. Epub 2022 Apr 21.
3
Eosinophilic Granulomatosis With Polyangiitis Diagnosed in an Elderly Female After the Second Dose of mRNA Vaccine Against COVID-19.
使用纳米材料递送核酸。
Mol Biomed. 2023 Dec 14;4(1):48. doi: 10.1186/s43556-023-00160-0.
4
Targeting ferroptosis opens new avenues for the development of novel therapeutics.靶向铁死亡为新型治疗药物的开发开辟了新途径。
Signal Transduct Target Ther. 2023 Sep 21;8(1):372. doi: 10.1038/s41392-023-01606-1.
5
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets.针对 SARS-CoV-2 的 T 细胞免疫:如果已知的最佳方法从长远来看并非最优方案,那该怎么办?适应不断变化的靶标。
Front Immunol. 2023 Jun 14;14:1133225. doi: 10.3389/fimmu.2023.1133225. eCollection 2023.
6
Next-Generation Vaccines: Nanovaccines in the Fight against SARS-CoV-2 Virus and beyond SARS-CoV-2.下一代疫苗:纳米疫苗在抗击 SARS-CoV-2 病毒及 SARS-CoV-2 之外的应用
Biomed Res Int. 2023 May 4;2023:4588659. doi: 10.1155/2023/4588659. eCollection 2023.
7
mRNA vaccines for cancer immunotherapy.mRNA 疫苗在癌症免疫治疗中的应用。
Front Immunol. 2022 Dec 14;13:1029069. doi: 10.3389/fimmu.2022.1029069. eCollection 2022.
在一名老年女性接种第二剂新冠mRNA疫苗后诊断出嗜酸性粒细胞肉芽肿性多血管炎
Cureus. 2022 Jan 12;14(1):e21176. doi: 10.7759/cureus.21176. eCollection 2022 Jan.
4
Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.≥65 岁成年人中同时接种高剂量四价流感疫苗和 mRNA-1273 新冠疫苗第三针的安全性和免疫原性:一项 2 期、随机、开放标签研究。
Lancet Respir Med. 2022 Apr;10(4):392-402. doi: 10.1016/S2213-2600(21)00557-9. Epub 2022 Feb 1.
5
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.新型冠状病毒 ARCoV mRNA 疫苗在中国成年人中的安全性和免疫原性:一项随机、双盲、安慰剂对照、1 期临床试验。
Lancet Microbe. 2022 Mar;3(3):e193-e202. doi: 10.1016/S2666-5247(21)00280-9. Epub 2022 Jan 24.
6
Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report.mRNA-1273疫苗接种后吉兰-巴雷综合征的亚急性发作:一例报告
SN Compr Clin Med. 2022;4(1):41. doi: 10.1007/s42399-022-01124-1. Epub 2022 Jan 18.
7
Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza.用于季节性或大流行性流感的多价mRNA候选疫苗的研发。
NPJ Vaccines. 2021 Dec 16;6(1):153. doi: 10.1038/s41541-021-00420-6.
8
A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques.一种多分支env-gag VLP mRNA疫苗可诱导2级HIV-1中和抗体,并降低猕猴感染异源SHIV的风险。
Nat Med. 2021 Dec;27(12):2234-2245. doi: 10.1038/s41591-021-01574-5. Epub 2021 Dec 9.
9
Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.BNT162b2 mRNA 疫苗标准和延长给药间隔的免疫原性。
Cell. 2021 Nov 11;184(23):5699-5714.e11. doi: 10.1016/j.cell.2021.10.011. Epub 2021 Oct 16.
10
Immunogenicity of -Transcribed RNA.-Transcribed RNA 的免疫原性。
Acc Chem Res. 2021 Nov 2;54(21):4012-4023. doi: 10.1021/acs.accounts.1c00521. Epub 2021 Oct 22.